Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Profit After Tax (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed Profit After Tax for 6 consecutive years, with -$20.4 million as the latest value for Q4 2020.

  • For Q4 2020, Profit After Tax fell 45.88% year-over-year to -$20.4 million; the TTM value through Dec 2020 reached -$73.2 million, down 30.53%, while the annual FY2025 figure was -$285.4 million, 10.46% up from the prior year.
  • Profit After Tax hit -$20.4 million in Q4 2020 for Syndax Pharmaceuticals, roughly flat from -$20.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$8.4 million in Q2 2016 and bottomed at -$20.4 million in Q3 2020.
  • Average Profit After Tax over 5 years is -$15.4 million, with a median of -$15.0 million recorded in 2016.
  • Year-over-year, Profit After Tax plummeted 110.34% in 2016 and then grew 26.27% in 2019.
  • Syndax Pharmaceuticals' Profit After Tax stood at -$10.8 million in 2016, then plummeted by 76.64% to -$19.1 million in 2017, then increased by 1.4% to -$18.8 million in 2018, then rose by 25.68% to -$14.0 million in 2019, then crashed by 45.88% to -$20.4 million in 2020.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$20.4 million, -$20.4 million, and -$17.1 million for Q4 2020, Q3 2020, and Q2 2020 respectively.